Epidemiology of oral contraceptives and cardiovascular disease

Annals of Internal Medicine

Volumn 128, Issue 6, 1998, Pages 467-477

  Chasan Taber, Lisa ^a,b   Stampfer, Meir J ^a,b,c  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b UNIVERSITY OF MASSACHUSETTS   (United States)

^c CHANNING LABORATORY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; ORAL CONTRACEPTIVE AGENT;

CARDIOVASCULAR DISEASE; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; FEMALE; HUMAN; MEDICAL INFORMATION; ORAL CONTRACEPTION; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SMOKING; SMOKING CESSATION;

EID: 0032521042     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-128-6-199803150-00008     Document Type: Review

References (91)

1. Gerstman BB, Gross TP. Kennedy DL. Bennett RC. Tomita DK, Stadel BV. Trends in the content and use of oral contraceptives in the United States, 1964-88. Am J Public Health. 1991:81:90-8.
2. Vessey MP. Epidemiologic studies of oral contraception. Int J Fertil. 1989; 34(Suppl):64-70.
3. Shapiro S, Slone D, Rosenberg U Kaufman DW, Stolley PD, Miettinen OS. Oral-contraceptive use in relation to myocardial infarction. Lancet. 1979; 1:743-7.
4. Rosenberg L, Kaufman DW, Helmrich SP, Miller DR, Stolley PD, Shapiro S. Myocardial infarction and cigarette smoking in women younger than 50 years of age. JAMA. 1985:253:2965-9.
5. Mann Jl, Vessey MP, Thorogood M, Doll R. Myocardial infarction in young women with special reference to oral contraceptive practice. Br Med J. 1975:2:241-5.
6. Jick H. Dinan B, Rothman KJ. Oral contraceptives and nonfatal myocardial infarction. JAMA. 1978:239:1403-6.
7. Petitti DB, Wingerd J, Pellegrin F, Ramcharan S. Risk of vascular disease in women. Smoking, oral contraceptives, noncontraceptive estrogens, and other factors. JAMA. 1979;242:1150-4.
8. Krueger DE, Ellenberg SS, Bloom S, Calkins BM, Jacyna R, Nolan DC et al. Risk factors for fatal heart attack in young women. Am J Epidemiol. 1981:113:357-70.
9. Sidney S, Petitti DB. Quesenberry CP Jr. Klatsky AU Ziel HK, Wolf S. Myocardial infarction in users of low-dose oral contraceptives. Obstet Gynecol. 1996:88:939-44.
10. Salonen JT. Oral contraceptives, smoking and risk of myocardial infarction in young women. A longitudinal population study in eastern Finland. Acta Med Scand. 1982;212:141-4.
11. Rosenberg L, Hennekens CH, Rosner B, Belanger C, Rothman KJ, Speizer FE. Oral contraceptive use in relation to nonfatal myocardial infarction. Am J Epidemiol. 1980:111:59-66.
12. Croft P, Hannaford PC. Risk factors for acute myocardial infarction in women: evidence from the Royal College of General Practitioners' oral contraceptive study. BMJ. 1989:298:165-8.
13. Adam SA, Thorogood M, Mann Jl. Oral contraception and myocardial infarction revisited: the effects of new preparations and prescribing patterns. Br J Obstet Gynaecol. 1981;88:838-45.
14. Cardiovascular disease and use of oral contraceptives. WHO Collaborative Study. Bull World Health Organ. 1989;67:417-23.
15. D'Avanzo B, La Vecchia C, Negri E. Parazzani F, Franceschi S. Oral contraceptive use and risk of myocardial infarction: an Italian case-control study. J Epidemiol Community Health. 1994;48:324-5.
16. Rosenberg U Palmer JR, Lesko SM, Shapiro S. Oral contraceptive use and the risk of myocardial infarction. Am J Epidemiol. 1990;131:1009-16.
17. Thorogood M, Mann J, Murphy M, Vessey M. Is oral contraceptive use still associated with an increased risk of fatal myocardial infarction? Report of a case-control study. Br J Obstet Gynaecol. 1991;98:1245-53.
18. Acute myocardial infarction and combined oral contraceptives: results of an international multicentre case-control study. WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Lancet. 1997;349: 1202-9.
19. Jensen G, Nyboe J, Appleyard M, Schnohr P. Risk factors for acute myocardial infarction in Copenhagen, II: Smoking, alcohol intake, physical activity, obesity, oral contraception, diabetes, lipids, and blood pressure. Eur Heart J. 1991;12:298-308.
20. Porter JB, Hunter JR, Jick H, Stergachis A. Oral contraceptives and nonfatal vascular disease. Obstet Gynecol. 1985:66:1-4.
21. Hirvonen E, Idänpään-Heikkilä J. Cardiovascular death among women under 40 years of age using low-estrogen oral contraceptives and intrauterine devices in Finland from 1975 to 1984. Am J Obstet Gynecol. 1990;163(1 Ft 2):281-4.
22. Lewis MA, Spitzer WO, Heinemann LA, MacRae KD, Bruppacher R, Thorogood M. Third generation oral contraceptives and risk of myocardial infarction: an international case-control study. Transnational Research Group on Oral Contraceptives and the Health of Young Women. BMJ. 1996;312: 88-90.
23. Jick H, Jick S, Myers MW, Vasilakis C Risk of acute myocardial infarction and low-dose combined oral contraceptives [Letter]. Lancet. 1996;347:627-8.
24. Porter JB, Jick H, Walker AM. Mortality among oral contraceptive users. Obstet Gynecol. 1987;70:29-32.
25. Vital Statistics of the United States. 1992. v.1. Mortality part B. Hyattsville. MD: US Dept of Health and Human Services, Centers for Disease Control and Prevention, National Center for Health Statistics; 1996:24-7.
26. Speroff L, DeCherney A. Evaluation of a new generation of oral contraceptives. The Advisory Board for the New Progestins. Obstet Gynecol. 1993;81: 1034-47.
27. Slone D, Shapiro S, Kaufman DW, Rosenberg L, Miettinen OS. Stolley PD. Risk of myocardial infarction in relation to current and discontinued use of oral contraceptives. N Engl J Med. 1981:305:420-4.
28. Stampfer MJ, Willett WC Colditz GA, Speizer FE, Hennekens CH. A prospective study of past use of oral contraceptive agents and risk of cardiovascular diseases. N Engl J Med. 1988:319:1313-7.
29. Mann Jl, Inman WH. Oral contraceptives and death from myocardial infarction. Br Med J. 1975:2:245-8.
30. La Vecchia C Franceschi S, Decarli A, Pampallona S, Tognoni G. Risk factors for myocardial infarction in young women. Am J Epidemiol. 1987:125: 832-43.
31. Mann Jl, Inman WH, Thorogood M. Oral contraceptive use in older women and fatal myocardial infarction. Br Med J. 1976:2:445-7.
32. Rosenberg L, Palmer JR, Shapiro S. Oral contraceptive use and myocardial infarction [Abstract]. CVD Epidemiology Newsletter. 1988:43:29.
33. Stampfer MJ, Willett WC Colditz GA, Speizer FE. Hennekens CH. Past use of oral contraceptives and cardiovascular disease: a meta-analysis in the context of the Nurses' Health Study. Am J Obstet Gynecol. 1990:163:285-91.
34. Engel HJ, Engel E, Lichtlen PR. Coronary atherosclerosis and myocardial infarction in young women-role of oral contraceptives. Eur Heart J. 1983;4:1-8.
35. Engel HJ, Hundeshagen H, Lichtlen P. Transmural myocardial infarction in young women taking oral contraceptives. Evidence of regional coronary flow in spite of normal coronary arteries. Br Heart J. 1977:39:477-84.
36. Jugdutt Bl, Stevens GF, Zacks DJ, Lee SJ, Taylor RF. Myocardial infarction, oral contraception, cigarette smoking, and coronary artery spasm in young women. Am Heart J. 1983:106:757-61.
37. Adams MR, Clarkson TB, Koritnik DR, Nash HA. Contraceptive steroids and coronary artery atherosclerosis in cynomolgus macaques. Fertil Steril. 1987:47:1010-8.
38. Clarkson TB, Shively CA, Morgan TM, Koritnik DR, Adams MR, Kaplan JR. Oral contraceptives and coronary artery atherosclerosis of cynomolgus monkeys. Obstet Gynecol. 1990:75:217-22.
39. Realini JP, Goldzieher JW. Oral contraceptives and cardiovascular disease: a critique of the epidemiologic studies. Am J Obstet Gynecol. 1985:152(6 pt 2):729-98.
40. Mishell DR Jr. Correcting misconceptions about oral contraceptives. Am J Obstet Gynecol. 1989:161:1385-9.
41. Stolley PD, Strom BL. Sartwell PE. Oral contraceptives and vascular disease. Epidemiol Rev. 1989:11:241-3.
42. Vessey MP, Lawless M, Yeates D. Oral contraceptives and stroke: findings in a large prospective study. Br Med J (Clin Res Ed). 1984;289:530-1.
43. Thorogood M. Mann J, Murphy M, Vessey M. Fatal stroke and use of oral contraceptives: findings from a case-control study. Am J Epidemiol. 1992; 136:35-45.
44. Haemorrhagic stroke, overall stroke risk, and combined oral contraceptives: results of an international, multicentre, case-control study. WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Lancet. 1996;348:505-10.
45. Hannaford PC, Croft PR. Kay CR. Oral contraception and stroke. Evidence from the Royal College of General Practitioners' Oral Contraception Study. Stroke. 1994:25:935-42.
46. Petitti DB. Sidney S, Bernstein A, Wolf S. Quesenberry C, Ziel HK. Stroke in users of low-dose oral contraceptives. N Engl J Med. 1996:335:8-15.
47. Longstreth WT, Nelson LM, Koepsell TD, van Belle G. Subarachnoid hemorrhage and hormonal factors in women. A population-based case-control study. Ann Intern Med. 1994;121:168-73.
48. Lidegaard O. Oral contraception and risk of a cerebral thromboembolitic attack: results of a case-control study. BMJ. 1993:306:956-62.
49. Ischaemic stroke and combined oral contraceptives: results of an international, multicentre. case-control study. WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Lancet. 1996:348:498505.
50. Tzourio C. Tehindrazanarivelo A. Iglesias 5, Alperovitch A, Chedru F, d'Anglejan-Chatillon J, et al. Case-control study of migraine and risk of ischaemic stroke in young women. BMJ. 1995:310:830-3.
51. Stadel BV. Oral contraceptives and cardiovascular disease. N Engl J Med. 1981:305:672-7.
52. Sartwell PE, Stolley PD. Oral contraceptives and vascular disease. Epidemiol Rev. 1982:4:95-109.
53. Jick H, Jick SS, Gurewich V, Myers MW, Vasilakis C Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components. Lancet. 1995; 246:1589-93.
54. Petitti DB, Wingerd J. Use of oral contraceptives, cigarette smoking, and risk of subarachnoid haemorrhage. Lancet. 1978;2:234-5.
55. Inman WH. Oral contraceptives and fatal subarachnoid haemorrhage. Br MedJ. 1979:2:1468-70.
56. Further analyses of mortality in oral contraceptive users. Royal College of General Practitioners' Oral Contraception Study. Lancet. 1981:1:541-6.
57. Oral contraception and increased risk of cerebral ischemia or thrombosis. Collaborative Group for the Study of Stroke in Young Women. N Engl J Med. 1973;288:871-8.
58. Oral contraceptives and stroke in young women. Associated risk factors. Collaborative Group for the Study of Stroke in Young Women. JAMA. 1975;231: 718-22.
59. Gerstman BB, Piper JM, Tomita DK, Ferguson WJ, Stadel BV, Lundin FE. Oral contraceptive estrogen dose and the risk of deep venous thromboembolitic disease. Am J Epidemiol. 1991:133:32-7.
60. Fuertes-de la Haba A, Curet JO, Pelegrina I, Bangdiwala I. Thrombophlebitis among oral and nonoral contraceptive users. Obstet Gynecol. 1971; 38:259-63.
61. Huisman MV, Buller HR, ten Cate JW, Vreeken J. Serial impedance plethysmography for suspected deep venous thrombosis in outpatients. The Amsterdam General Practitioners Study. N Engl J Med. 1986:314:823-8.
62. tensing AW, Prandoni P, Brandjes D, Huisman PM, Vigo M, Tomasella G, et al. Detection of deep-vein thrombosis by real-time B-mode ultrasonography. N Engl J Med. 1989;320:342-5.
63. Böttiger LE, Boman G, Eklund G, Westerholm B. Oral contraceptives and thromboembolic disease: effects of lowering oestrogen content. Lancet. 1989:8178:1097-101.
64. Helmrich SP, Rosenberg L, Kaufman DW, Strom B, Shapiro S. Venous thromboembolism in relation to oral contraceptive use. Obstet Gynecol. 1987:69:91-5.
65. Thorogood M, Mann J, Murphy M, Vessey M. Risk factors for fatal venous thromboembolism in young women: a case-control study. Int J Epidemiol. 1992:21:48-52.
66. Vandenbroucke JP, Koster T, Briet E, Reitsma PH, Bertina RM, Rosendaal FR. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet. 1994:344:1453-7.
67. Beaumont V, Malinow MR, Sexton G, Wilson D, Lernort N, Upson B, et al. Hyperhomocyst(e)inemia, anti-estrogen antibodies and other risk factors for thrombosis in women on oral contraceptives. Atherosclerosis. 1992; 94:147-52.
68. Vessey M, Mant D, Smith A, Yeates D. Oral contraceptives and venous thromboembolism: findings in a large prospective study. Br Med J (Clin Res Ed). 1986:292:526.
69. Kühl H, Jung-Hoffman C Heidt F. Alterations in the serum levels of gestodene and SHBG during 12 cycles of treatment with 30 micrograms ethinylestradiol and 75 micrograms gestodene. Contraception. 1988:38:477-86.
70. Kühl H, Jung-Hoffmann C, Heidt F. Serum levels of 3 keto-desogestrel and SHBG during 12 cycles of treatment with 30 micrograms ethinylestradiol and 150 micrograms desogestrel. Contraception. 1988;38:381-90.
71. Kuhnz W. Pharmacokinetics of the contraceptive steroids levonorgestrel and gestodene after single and multiple oral administration to women. Am J Obstet Gynecol. 1990; 163(6 Pt 2):2120-7.
72. Kumpel M. Tuber U. Kuhnz W, Pfeffer M, Brill K, Heithecker R, et al. Comparison of serum ethinyl estradiol, sex-hormone-binding globulin, corticoid-binding globulin and Cortisol levels in women using two low-dose combined oral contraceptives. Horm Res. 1990:33:35-9.
73. Dillner L Pill scare linked to rise in abortions [Letter). Br Med J. 1996:312:996.
74. Child TJ. Rees M, MacKenzie IZ. Pregnancy terminations after oral contraception scare [Letter]. Lancet. 1996:347:1260-1.
75. Lewis MA, Heinemann LA, MacRae KD, Bruppacher R, Spitzer WO. The increased risk of venous thromboembolism and the use of third generation progestagens: role of bias in observational research. The Transnational Research Group on Oral Contraceptives and the Health of Young Women. Contraception. 1996;54:5-13.
76. Spitzer WO, Lewis MA, Heinemann LA. Thorogood M, MacRae KD. Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control study. Transnational Research Group on Oral Contraceptives and the Health of Young Women. BMJ. 1996:312:83-8.
77. Venous thromboembolic disease and combined oral contraceptives: results of international multicentre case-control study. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Lancet. 1995;346:1575-81.
78. Farmer RD, Lawrenson RA, Thompson CR, Kennedy JG, Hambleton IR. Population-based study of risk of venous thromboembolism associated with various oral contraceptives. Lancet. 1997;349:83-8.
79. Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Lancet. 1995; 346:1582-8.
80. Lidegaard O. Milsom I. Oral contraceptives and thrombotic diseases: impact of new epidemiologic studies [Editorial]. Contraception. 1996:53:135-9.
81. Bloemenkamp KW, Rosendaal FR. Heimerhorst FM, Buller HR. Vandenbroucke JP. Enhancement by factor V Leiden mutation or risk of deepvein thrombosis associated with oral contraceptives containing a third-generation progestagen. Lancet. 1995:346:1593-6.
82. Meade TW, Greenberg G, Thompson SG. Progestogens and cardiovascular reactions associated with oral contraceptives and a comparison of the safety of 50- and 30-microgram oestrogen preparations. Br Wed J. 1980;280:1157-61.
83. Kay CR. Progestogens and arterial disease-evidence from the Royal College of General Practitioners' Study. Am J Obstet Gynecol. 1982;142:762-5.
84. Gerstman BB, Piper JM. Freiman JP, Tomita DK. Kennedy DU Ferguson WJ, et al. Oral contraceptive oestrogen and progestin potencies and the incidence of deep venous thromboembolism. Int J Epidemiol. 1990; 19:931-6.
85. Robinson GE. Low-dose combined oral contraceptives. Br J Obstet Gynaecol. 1994;101:1036-41.
86. Stubblef ield PG. Cardiovascular effects of oral contraceptives: a review. Int J Fertil. 1990;34(Suppl):40-9.
87. Rosing J, Tans G, Nicolaes GA, Thomassen MC van Oerle R, van der Ploeg PM, et al. Oral contraceptives and venous thrombosis: different sensitivities to activated protein C in women using second- and third-generation oral contraceptives. Br J Haematol. 1997;97:233-8.
88. Rosendaal FR, Koster T, Vandenbroucke JP, Reitsma PH. High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance). Blood. 1995;85:1504-8.
89. Conard J, Horellou MH, Van Dreden P, Lecompte T, Samama M. Thrombosis and pregnancy in congenital deficiencies in AT III, protein C or protein S: study of 78 women. Thromb Haemost. 1990;63:319-20.
90. Prevention of venous thrombosis and pulmonary embolism. NIH Consensus Development. JAMA. 1986:256:744-9.
91. Vandenbrouke JP, Rosendaal FR. End of the line for third-generation-pill controversy? [Letter] Lancet. 1997:349:1113-4.